{
  "metadata": {
    "timestamp": "2025-12-17T21:49:11.810087",
    "genes": [
      "CAMK2D",
      "MIR4435-2HG",
      "CDK6",
      "CYTOR",
      "CHRM3",
      "RGS6",
      "KIAA1211L",
      "KLHL4",
      "CDH2",
      "HIVEP3",
      "SPRY4",
      "TRIO",
      "ADAMTS9",
      "WWTR1",
      "SPRED2",
      "VAV3",
      "PLAT",
      "SATB2",
      "CHRM3-AS2",
      "SIPA1L1",
      "GAP43",
      "KCNIP1",
      "PCNX2",
      "GRIA3",
      "ILDR2",
      "IL1RAP",
      "AC092691.1",
      "CPNE4",
      "IQGAP2",
      "BCAT1",
      "TRIM9",
      "LRATD1",
      "NOVA1",
      "METTL7B",
      "JAG1",
      "DENND2A",
      "PALM2-AKAP2",
      "SPRED1",
      "NRCAM",
      "FREM2",
      "DPF3",
      "SPATA6",
      "CNKSR2",
      "HS2ST1",
      "TNFRSF12A",
      "GLDC",
      "MYO16",
      "CHL1",
      "CDK14",
      "CDH4",
      "NEK6",
      "STK17A",
      "STK32A",
      "STK32B",
      "MED12L",
      "CAMK2B",
      "ARHGEF26",
      "ARSJ",
      "C6ORF141",
      "GALR1",
      "PTPRZ1",
      "SH3PXD2B",
      "RHOJ",
      "SHROOM3",
      "ITGB8",
      "CREB5",
      "AC092958.1",
      "INSYN2A",
      "LYST",
      "CSMD2",
      "ITGA3",
      "ITGA7",
      "KLHL29",
      "AC124254.2",
      "DPP6",
      "KANK1",
      "ZDHHC14",
      "PREX1",
      "P2RY14",
      "AC004828.2",
      "SLC35F1",
      "CPNE8",
      "TANC1",
      "IGF2BP2",
      "EML4",
      "ADAM19",
      "COL22A1",
      "ACSS3",
      "SRPX",
      "FRMD5",
      "MEIS1",
      "ESR2",
      "SEMA5A",
      "ENC1",
      "SYNJ2",
      "COL4A2",
      "MEG8",
      "SEMA3E",
      "MAP3K1",
      "POSTN",
      "DLC1",
      "DNMBP",
      "ETV5",
      "DEC1",
      "ABCC3",
      "LONRF2",
      "CEMIP",
      "LINC02742",
      "SHISA9",
      "ETV6",
      "MAMLD1",
      "ERI1",
      "FGF14",
      "SNTG1",
      "FNDC3B",
      "CLMN",
      "SPRY2",
      "PRAG1",
      "SLC8A1",
      "LSAMP",
      "LMO2",
      "DNM1",
      "PDE8A",
      "AC087564.1",
      "GRIK2",
      "RCAN1",
      "GRIN2B",
      "ALK",
      "VMP1",
      "AL356124.1",
      "LEF1",
      "HMGA2",
      "HMGA2-AS1",
      "LDLRAD3",
      "IGF2BP3",
      "PCDH7",
      "LAMC1",
      "PCDH9-AS2",
      "TRPM3",
      "ACSBG1",
      "NES",
      "ADGRL3",
      "ADAM12",
      "HS3ST5",
      "ADAMTS9-AS1",
      "MTCL1",
      "UBASH3B",
      "ARHGAP26",
      "RASSF8",
      "AC017002.5",
      "PGAP1",
      "LIMK1",
      "RYR3",
      "AC060834.2",
      "ZMAT4",
      "KCNMA1",
      "SCD5",
      "SAMD4A",
      "RUNX1",
      "NPAS3",
      "AC064875.1",
      "SCG2",
      "GAS2",
      "OSBP2",
      "PDGFA",
      "LAMA4",
      "SLC35F4",
      "EMP1",
      "KCND2",
      "DPYSL5",
      "RFFL",
      "KALRN",
      "ITPR2",
      "LAMA2",
      "SLC1A2",
      "ELOVL2",
      "L3MBTL4",
      "DPY19L1",
      "RBPMS",
      "RGS17",
      "LPAR1",
      "DUSP6",
      "LINC01138",
      "RNF157",
      "PXYLP1",
      "LHFPL6",
      "FBN2",
      "RUBCNL",
      "FGFR1",
      "SH3KBP1",
      "GRB10",
      "GPR158",
      "LINC01798",
      "EPHA3",
      "PTPRJ",
      "GNG12-AS1",
      "PRKD1",
      "PVT1",
      "LINC00266-1",
      "SEMA3A"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_7",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nLet me analyze this comprehensive gene list in the context of astrocytoma. The user is asking for a detailed literature analysis identifying gene programs - clusters of genes acting together in pathways, processes, or cellular states.\n\nFirst, let me understand what I have:\n- A large list of genes (170+)\n- Context: Astrocytoma (brain tumor derived from astrocytes)\n- Task: Identify functional gene programs, clusters, and their implications\n\nThe search results provided include:\n- Various NCBI gene pages (mostly metadata)\n- Several Nature articles on recent research topics including:\n  - Alzheimer's disease gene networks\n  - TBI (traumatic brain injury) and astrocyte activation\n  - Glioma and neuronal interaction\n  - Mitochondrial dysfunction in senescence\n  - Talin and integrin-mediated adhesion\n  - Depression-related astrocytic metabolism\n\nLet me plan my approach:\n\n1. I need to create a 10,000+ word comprehensive report\n2. Identify major functional clusters among the genes provided\n3. Connect them to astrocytoma biology and pathology\n4. Provide evidence from the search results and general knowledge\n5. Include a JSON output following the schema\n\nKey functional groups I can identify from the gene list:\n\n1. **Cell adhesion and junction proteins**: CDH2, CDH4, NRCAM, JAG1, ITGA3, ITGA7, ITGB8, LAMC1, COL4A2, COL22A1, LAMA2, LAMA4, FREM2, CSMD2, CHL1\n   - Relevant to: invasion, EMT, tumor progression\n\n2. **Signaling kinases and GTPases**: CDK6, CDK14, CAMK2B, CAMK2D, STK17A, STK32A, STK32B, NEK6, VAV3, MAP3K1, PREX1, ALK, LIMK1, FGFR1\n   - Relevant to: proliferation, survival, migration\n\n3. **RAS pathway regulation and Rho signaling**: RGS6, RGS17, SPRY4, SPRY2, SPRED2, SPRED1, DUSP6, ETV5, ETV6, ARHGEF26, ARHGAP26, RHOJ, DLC1\n   - Relevant to: MAPK/ERK regulation, Rho GTPase signaling\n\n4. **Ion channels and transporters**: These genes play critical roles in cellular excitability, signal transduction, and metabolic processes. The identified genes like KCNMA1, KCND2, TRPM3, GRIA3, GRIN2B, and CHR suggest complex neuronal and cellular communication mechanisms potentially influencing astrocytoma progression and cellular behavior.\n\nI'll focus on mapping these gene clusters to specific molecular pathways and their potential implications in astrocytoma development and progression. I'll focus on synthesizing the key insights from the gene categories, highlighting their interconnected roles in astrocytoma biology.\n\nThe identified gene clusters reveal complex molecular mechanisms underlying astrocytoma progression. Neuronal and synaptic genes suggest intricate interactions between tumor cells and neural environments. Transcriptional regulators like SATB2 and RUNX1 indicate potential differentiation and stemness dynamics. Metabolic and mitochondrial genes point to fundamental cellular adaptations that support tumor survival and stress responses.\n\nExtracellular matrix components, particularly POSTN and ADAM proteins, likely facilitate tumor invasion and microenvironmental remodeling. Calcium signaling genes hint at critical regulatory pathways influencing cellular excitability and communication.\n\nThese molecular programs collectively illuminate the multifaceted nature of astrocytoma's biological complexity, bridging genetic, metabolic, and functional domains.\n</think>\n\n# Comprehensive Gene Program Analysis in Astrocytoma: Functional Clustering and Mechanistic Insights\n\nAstrocytomas represent a significant class of central nervous system malignancies, with their biology fundamentally shaped by the dysregulation of astrocyte-specific and general cellular processes. The 170 genes provided constitute a substantial molecular signature with potential relevance to multiple aspects of astrocytoma pathogenesis, including transformation, invasion, metabolic reprogramming, and interactions with the tumor microenvironment. This report presents a systematic analysis of these genes as functional programs—coordinated gene clusters operating within specific biological pathways and cellular processes—anchored in the established literature on astrocyte physiology and astrocytoma oncobiology. Through integrative analysis of gene interactions, regulatory networks, and pathway dynamics, we identify eleven major gene programs spanning cell adhesion and invasion, kinase signaling, metabolic reprogramming, synaptic dysfunction, and transcriptional control. Each program is evaluated for its potential contribution to tumor progression while considering both the cell-autonomous properties of neoplastic astrocytes and their interactions with the broader tumor microenvironment.\n\n## Integrin-Mediated Cell Adhesion and Mechanotransduction Program\n\nThe adhesion and mechanotransduction program emerges as a central hub coordinating cellular interactions with the extracellular matrix and neighboring cells. This program encompasses integrin heterodimers, focal adhesion scaffolds, and downstream signaling cascades that transduce mechanical cues into biochemical signals. Within the input gene list, the program includes integrin alpha subunits (ITGA3, ITGA7), integrin beta-8 (ITGB8), and multiple structural proteins that mediate cell-matrix interactions. Notably, talin force coupling represents a critical molecular mechanism by which integrins activate in response to mechanical tension, requiring the coordinated function of integrin cytoplasmic tails, talin head domains, and downstream actin-binding proteins[56]. The presence of LIMK1 and ARHGAP26 in the input list suggests that Rho-family GTPases, which regulate actin dynamics through their effectors, likely contribute to mechanotransduction in these astrocytoma cells. \n\nIntegrin-mediated signaling has been directly implicated in glioma cell migration and invasion, two hallmark features of malignant astrocytomas. ITGA3 and ITGA7, encoding alpha-3 and alpha-7 integrin subunits respectively, participate in heterodimeric complex formation with beta-1 integrins to engage collagen and laminin in the extracellular matrix. The laminin-binding integrins present in astrocytomas would support adhesion to basement membranes during invasion of the brain parenchyma and blood vessels. ITGB8, an integrin beta subunit with more restricted expression patterns, associates with alpha-V to form a receptor for fibronectin and other ligands; its presence in this gene list suggests active matrix remodeling and cellular migration phenotypes. Mechanotransduction through these adhesion receptors activates focal adhesion kinase (FAK), phosphorylates paxillin at critical tyrosine residues, and promotes the nuclear translocation of YAP/TAZ transcriptional co-activators—a cascade that is often dysregulated in cancer[56]. While FAK itself does not appear in the input list, multiple downstream effectors do, suggesting that integrin signaling may be partially uncoupled from canonical FAK activation in these cells.\n\nThe adhesion program also includes extracellular matrix proteins that serve as ligands and modulators of integrin signaling. POSTN (periostin), a matricellular protein, was recently shown to promote sarcoma growth and metastasis by recruiting tumor-associated macrophages and suppressing anti-tumor immune responses[30]. In astrocytomas, periostin is often upregulated in the tumor stroma and tumor cells themselves, promoting a pro-tumoral microenvironment through non-cell-autonomous mechanisms. LAMC1 and LAMA2 encode laminin gamma-1 and alpha-2 chains, major components of basement membrane and extracellular matrix that serve as scaffolds for cell migration and differentiation. Collectively, this program is predicted to enhance focal adhesion assembly, promote mechanically regulated gene expression through YAP/TAZ signaling, and facilitate invasion through ECM remodeling, all processes central to astrocytoma progression.\n\n## Rho GTPase Signaling and Cytoskeletal Organization Program\n\nRho-family GTPases represent critical intracellular switches controlling actin dynamics, cell migration, and invasion. The input gene list contains multiple regulators of Rho GTPase signaling that collectively form a sophisticated program for controlling RhoA, Rac1, and Cdc42 activities. This program includes guanine nucleotide exchange factors (GEFs) such as ARHGEF26 and TRIO, which catalyze the exchange of GDP for GTP to activate these proteins; GTPase-activating proteins (GAPs) such as DLC1, ARHGAP26, and SIPA1L1, which inactivate GTPases by promoting GTP hydrolysis; and negative feedback regulators such as VAV3, which itself acts as a GEF for Rac1 and Cdc42 in response to receptor signaling. Previous studies have demonstrated that DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA[12], suggesting that dysregulation of DLC1 in astrocytomas may contribute to uncontrolled cell motility.\n\nRHOJ, encoding a GTPase family member, is present in the list and may contribute to Rho-dependent contractility and migration. The Rho-ROCK pathway, where ROCK1 serves as a key effector, promotes the formation of stress fibers and cell contractility necessary for invasion. While ROCK1 itself is not in the input list, the presence of multiple Rho pathway regulators (RGS6, RGS17, SPRY2, SPRY4, SPRED1, SPRED2) indicates robust negative feedback on growth factor signaling that converges on Rho activation. RGS (Regulator of G-protein Signaling) proteins inhibit heterotrimeric G-protein signaling and often indirectly suppress Rho-GEF activation, thus dampening Rho signaling. Sprouty and Spred proteins are well-characterized negative feedback regulators of receptor tyrosine kinase (RTK) signaling pathways, including the MAPK/ERK cascade, suggesting a brake on growth factor-driven proliferation and migration.\n\nThe cytoskeletal program operates in concert with the adhesion program to control cell shape, migratory velocity, and invasive capacity. Genes encoding actin-binding proteins and their regulators—such as SHROOM3 (a regulator of apical-basal polarity that influences cell migration), TRIM9 (an E3 ubiquitin ligase affecting cytoskeletal dynamics), and LIMK1 (a kinase that phosphorylates and inactivates cofilin to stabilize actin filaments)—collectively enable the dynamic reorganization of the actin cytoskeleton required for migration. In astrocytomas, enhanced Rho signaling combined with weakened negative feedback (through loss or downregulation of GAPs and RGS proteins) would promote excessive actin polymerization, stress fiber formation, and cell migration. Conversely, dysregulation of these brakes could lead to uncontrolled migration.\n\n## Kinase Signaling Cascades and Cell Proliferation Program\n\nThe proliferation program encompasses a diverse set of kinases that control cell cycle progression, survival signaling, and growth factor responses. This program includes cyclin-dependent kinases (CDK6, CDK14), Ca²⁺/calmodulin-dependent protein kinases (CAMK2B, CAMK2D), serine-threonine kinases (STK17A, STK32A, STK32B, NEK6), the neuron-specific tyrosine kinase SYN (FYN is listed), and the anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase frequently dysregulated in various malignancies. CDK6 is particularly relevant to astrocytomas, as it drives G1-to-S phase transition and is often overexpressed in high-grade gliomas through amplification of the chromosome 7q locus where CDK6 resides. ALK, when dysregulated through fusion events or amplification, contributes to constitutive kinase signaling that drives proliferation and transformation[17][19].\n\nMAP3K1, encoding a mitogen-activated protein kinase kinase kinase, sits upstream of MAPK/ERK and JNK signaling cascades that control proliferation, differentiation, and stress responses. The presence of PREX1, a phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchange factor, suggests that the PI3K/Akt pathway, a major survival and proliferation pathway often activated in astrocytomas through PIK3CA mutations or PTEN loss, contributes to this program. CAMK2B and CAMK2D, which are calcium-dependent protein kinases, may link calcium signaling (a prominent feature of astrocyte physiology) to proliferation and migration. The CAMK pathway is activated downstream of NMDA-type glutamate receptors and is essential for neuronal plasticity; in astrocytomas that dysregulate glutamate handling, CAMK signaling may become inappropriately activated to promote proliferation[42].\n\nWhile the input list includes negative regulators of growth signaling (RGS, Sprouty, and Spred proteins as noted above), the net balance in astrocytoma cells is predicted to favor proliferation, as oncogenic kinase signaling often overcomes negative feedback. This program is expected to drive enhanced cell cycle progression, reduced apoptosis, and prolonged survival of neoplastic astrocytes.\n\n## MAPK/ERK Pathway Regulation Through Feedback Control Program\n\nClosely related to but distinct from the broader kinase signaling program is a specialized regulatory network controlling MAPK/ERK signaling through negative feedback loops. The input list contains multiple negative regulators of this pathway: SPRY2, SPRY4, SPRED1, SPRED2, and DUSP6. These genes encode proteins that collectively suppress MAPK/ERK signaling at multiple levels. Sprouty proteins inhibit RTK signaling through multiple mechanisms, including sequestration of Grb2 adaptor proteins and inhibition of Ras activation. Spred proteins similarly suppress Ras-Raf-MEK-ERK signaling. DUSP6, a member of the dual-specificity phosphatase family, directly dephosphorylates and inactivates ERK1/2, providing rapid feedback suppression. \n\nIn normal astrocytes, these feedback mechanisms maintain tight control over MAPK signaling in response to growth factors and cytokines. In astrocytomas, dysregulation of these suppressors—either through loss of expression, mutation, or epigenetic silencing—combined with activation of upstream kinases (through RAS or BRAF mutations, or receptor tyrosine kinase amplification) creates a permissive environment for sustained MAPK/ERK signaling. Conversely, the presence of these negative regulators in the input gene list might suggest either that their suppression is a key event in transformation, or that their residual activity constrains proliferation in certain astrocytoma subtypes. The transcriptional output of MAPK/ERK signaling includes proliferation genes, EMT-related factors, and pro-survival signals, all relevant to astrocytoma progression.\n\n## Calcium Signaling and Neuronal-Astrocyte Interaction Program\n\nCalcium signaling represents a fundamental mechanism by which astrocytes integrate extracellular and intracellular cues and communicate with neurons. The input gene list contains multiple components of the calcium signaling machinery, including ion channels (TRPM3, GRIN2B, GRIA3, KCNMA1, KCND2) and calcium-handling proteins (ITPR2, RYR3, CAMK2B, CAMK2D). ITPR2, the inositol 1,4,5-trisphosphate receptor type 2, is a calcium channel in the endoplasmic reticulum (ER) that couples phospholipase C signaling to calcium release from intracellular stores. Recent work has demonstrated that ITPR2-mediated calcium release is critical for mitochondrial calcium uptake and the promotion of cellular senescence in response to various stress signals[21][22]. In astrocytomas, dysregulation of ITPR2 could alter calcium homeostasis, promote mitochondrial dysfunction, and either suppress or enhance senescence depending on context.\n\nGRIN2B and GRIA3 encode NMDA and AMPA-type glutamate receptors, respectively. While these are classically viewed as neuronal receptors, emerging evidence indicates that astrocytes express functional glutamate receptors that mediate their responses to synaptic glutamate. In astrocytomas growing in the brain, the tumor cells are surrounded by neurons and synaptic terminals; aberrant expression of glutamate receptors in tumor astrocytes could enable inappropriate calcium signaling in response to synaptic activity or ectopic glutamate release by the tumor itself[42]. KCNMA1 and KCND2 encode voltage-gated potassium channels (large-conductance and fast inactivating A-type channels, respectively) that regulate cellular excitability. Astrocytes primarily express different potassium channels (including inward rectifiers), but their dysregulation in astrocytomas could affect calcium buffering and cell migration.\n\nCHRM3 and P2RY14 encode G-protein-coupled receptors (a muscarinic acetylcholine receptor and a purinergic receptor, respectively) that trigger intracellular calcium release through Gq-coupled signaling cascades[2]. In astrocytes, these receptors are activated by synaptic transmitters (acetylcholine, ATP) and initiate calcium waves that propagate through gap junctions and trigger the release of gliotransmitters. In astrocytomas, dysregulation of these receptors could drive calcium-dependent proliferation, migration, or crosstalk with the neural microenvironment. Importantly, recent evidence has revealed that astrocytic mitochondrial connexin-43 (Cx43), while not directly in this list, regulates IDH3α to maintain glycolytic metabolism and lactate production essential for neuronal excitability in normal brain[43]. Dysregulation of mitochondrial calcium handling and metabolism could alter this astrocyte-neuron coupling and promote tumor growth.\n\n## Synaptic Organization and Neuron-Tumor Interaction Program\n\nA substantial subset of the input gene list encodes proteins classically associated with synaptic function, neuronal development, and neuron-astrocyte interactions. These include growth-associated protein 43 (GAP43), synaptojanin-2 (SYNJ2), kinesin light chain proteins (implied through KANK1), neuronal cell adhesion molecules (NRCAM, CHL1, LSAMP), and glutamate receptors (GRIA3, GRIN2B, GRIK2). GAP43, also known as neuromodulin, is a well-characterized marker of axonal regeneration and growth cone development; its expression in astrocytomas is thought to reflect a permissive microenvironment for neuronal growth or aberrant neural-like differentiation[47]. NRCAM (neuronal cell adhesion molecule) mediates axon-axon and axon-glia interactions, and its expression in astrocytomas could facilitate physical interactions between tumor cells and neurons[39].\n\nThe presence of genes encoding synaptic proteins in astrocytomas is striking and suggests either that these tumors retain a program of neural development or interaction, or that they actively upregulate synaptic genes to manipulate the neuronal microenvironment. Recent work has demonstrated that tumor-derived glutamate, acting through neuronal NMDA and AMPA receptors, drives aberrant neuronal excitability and promotes seizures in peritumoral cortex[42]. The presence of glutamate receptor subunits and associated signaling proteins in astrocytomas suggests that tumors may also directly participate in glutamate signaling. Additionally, synaptogenic factors produced by specific astrocyte populations have been linked to tumor-associated seizures, implicating dysregulated astrocyte-neuron interactions as a key feature of high-grade glioma pathobiology[42].\n\nCREB5, a cAMP response element-binding protein, is a transcription factor that integrates calcium and cAMP signaling to control gene expression. In astrocytes, CREB phosphorylation downstream of calcium influx through voltage-gated calcium channels or NMDA receptors drives the expression of neuroprotective and growth-promoting genes. In astrocytomas, dysregulation of CREB5 could shift the balance between pro-tumoral and anti-tumoral programs. The combined dysregulation of calcium signaling, synaptic machinery, and CREB-dependent transcription in astrocytomas likely explains their unique capacity to interact extensively with neurons and promote peritumoral neuronal dysfunction.\n\n## Transcriptional Regulation and Cellular Differentiation Program\n\nAstrocytes undergo progressive differentiation during brain development, transitioning from neural progenitors to mature astrocytes with characteristic morphology, gene expression, and functional properties. The input gene list contains multiple transcription factors implicated in astrocyte differentiation and identity: SATB2 (special AT-rich sequence binding protein 2), LEF1 (lymphoid enhancer-binding factor 1), RUNX1 (runt-related transcription factor 1), CREB5, LMO2 (LIM domain only 2), MEIS1 (meis homeobox 1), HMGA2 (high-mobility group AT-hook 2), NPAS3 (neuronal PAS domain protein 3), and ENC1 (ectodermal-neural cortex 1).\n\nSATB2 is a matrix attachment region-binding protein that functions as a potent transcription factor promoting osteoblastogenesis and bone regeneration[23][26]. In the nervous system, SATB2 is involved in axonal outgrowth and connectivity. LEF1 is a key component of Wnt signaling and is required for neural progenitor maintenance and fate decisions. RUNX1 is essential for hematopoietic differentiation but is also expressed in neural tissues where it influences developmental programs. MEIS1 and LMO2 function as cofactors for HOXA cluster genes, which establish developmental hierarchies during hematopoiesis and likely contribute to neural patterning as well[24][27]. HMGA2 is a high-mobility group protein that functions as a architectural transcription factor and is frequently upregulated in cancers through amplification or t(12;15) translocations, where it drives undifferentiated and stem-like phenotypes.\n\nIn astrocytomas, dysregulation of this transcriptional program is expected to maintain cells in a more progenitor-like or dedifferentiated state, preventing terminal astrocytic differentiation and preserving proliferative capacity. High-grade astrocytomas often display reduced expression of mature astrocytic markers (GFAP, glutamine synthetase) and elevated expression of progenitor markers (nestin, Sox2, Olig2), consistent with a dedifferentiation or block in differentiation. The input list suggests that transcriptional regulators controlling neural progenitor identity and developmental processes are dysregulated in ways that promote stemness and self-renewal in neoplastic astrocytes.\n\n## Extracellular Matrix Remodeling and Invasion Program\n\nThe invasion program encompasses genes encoding extracellular matrix proteins, matrix-degrading proteases, and their regulators. This includes ADAMTS9 and ADAMTS9-AS1 (a disintegrin and metalloproteinase with thrombospondin motifs 9 and its long non-coding RNA), ADAM19 and ADAM12 (ADAM domain proteases with substrate specificity for different ECM components), and MMP14 (matrix metallopeptidase 14, also known as MT1-MMP), a membrane-anchored protease critical for ECM remodeling during invasion[31]. ADAMTS proteases cleave aggrecan, versican, and other ECM components, while ADAM proteases participate in shedding of cell surface proteins and ECM remodeling. MMP14 operates at the interface between tumor cells and the ECM, creating local zones of ECM degradation that enable cell invasion.\n\nPOSTN (periostin) functions as a matricellular protein—a category of secreted proteins that regulate cell-ECM interactions without providing primary structural support. Periostin promotes invasion, metastasis, and immune suppression in multiple cancer types through non-cell-autonomous mechanisms involving immune cell recruitment and reprogramming[30][32]. The presence of both ECM components (LAMC1, LAMA2, LAMA4, COL4A2, COL22A1, FBN2) and remodeling enzymes (ADAMTS9, ADAM19, ADAM12, MMP14) in the input list suggests an active program of ECM remodeling in these astrocytomas, with implications for invasion, migration, and immune cell infiltration. SRPX (sushi repeat-containing protein X), a secreted protein, and FRMD5 (FERM domain-containing 5), a cytoplasmic scaffolding protein, may contribute to the coordination of cell-ECM interactions during migration.\n\n## Metabolic Reprogramming Program\n\nAstrocytomas, like most cancers, undergo profound metabolic rewiring to support rapid growth while adapting to the hypoxic and glucose-rich brain environment. The input list contains multiple metabolic genes: BCAT1 (branched-chain amino acid transaminase 1), GLDC (glycine cleavage system protein H), ACSBG1 (acyl-CoA synthetase butyrate-CoA ligase 1), ACSS3 (acyl-CoA synthetase short-chain family member 3), ELOVL2 (ELOVL fatty acid elongase 2), OSBP2 (oxysterol binding protein 2), and VMP1 (vacuole membrane protein 1). BCAT1 catalyzes the transamination of branched-chain amino acids (leucine, isoleucine, valine) to branched-chain alpha-ketoacids, linking amino acid and energy metabolism. GLDC encodes a component of the glycine cleavage system, which converts glycine to CO2, ammonia, and a one-carbon unit; dysregulation of this pathway has been implicated in various malignancies.\n\nACSBG1 and ACSS3 activate short- and medium-chain fatty acids for entry into lipid synthesis and energy metabolism pathways. ELOVL2 elongates polyunsaturated fatty acids, a process important for membrane biogenesis and signaling lipid synthesis. Metabolic alterations in astrocytomas include shift toward aerobic glycolysis (Warburg effect), enhanced glutamine utilization (glutaminolysis), and increased lipid synthesis to support rapid membrane production for cell growth and division. The astrocytoma metabolic program is predicted to enhance glucose and glutamine uptake, promote aerobic glycolysis and mitochondrial dysfunction, and increase biosynthetic precursor generation for cell growth.\n\n## Migration and Guidance Program\n\nCellular migration requires coordinated regulation of adhesion, cytoskeletal dynamics, and directional cue sensing. The input list contains genes encoding guidance cues (SEMA5A, SEMA3A, SEMA3E) and their receptors, as well as migration-associated kinases and scaffolding proteins. SEMA5A, SEMA3A, and SEMA3E are semaphorins, secreted or membrane-bound signaling proteins that were originally discovered as axon guidance cues but are now recognized as critical regulators of cell migration in multiple contexts. Semaphorins interact with plexin and neuropilin receptors to trigger repulsion or attraction. In gliomas, semaphorins can drive or suppress invasion depending on the specific semaphorin-receptor pair and cellular context.\n\nETV5 and ETV6, encoding ETS transcription factors, regulate target genes in response to MAPK/ERK signaling and participate in both normal development and oncogenic transformation. Notably, EML4-ALK fusion proteins, which are frequent in non-small cell lung cancer and can occur in some neural tumors, activate MAPK and PI3K signaling to promote cell migration and invasion[19]. The presence of ALK and EML4 in the input list suggests that this fusion event may occur in some astrocytomas or related neural tumors. DPP6, a dipeptidyl peptidase, is involved in regulation of voltage-gated ion channels and may influence neuronal excitability; its role in astrocytoma migration is less well characterized but may relate to calcium signaling or neuronal interaction.\n\n## Neurotrophic Signaling and Survival Program\n\nNeurotrophic factors and their receptors are essential for neuronal survival, growth, and differentiation during development and in response to injury. While classical neurotrophic receptors (TrkA, TrkB, TrkC) are not directly in the input list, genes encoding their co-receptors and signaling effectors are present. p75 neurotrophin receptor (NTR) signaling, which can promote either survival or apoptosis depending on context, is suggested by the presence of TNFRSF12A (tumor necrosis factor receptor superfamily member 12A, also known as TWEAK receptor). TNFRSF12A mediates signaling by TWEAK, a TNF-related ligand that promotes inflammation, cell survival, and in some contexts, cell death. In astrocytomas, TWEAK-TNFRSF12A signaling could promote inflammatory microenvironment changes that support tumor growth.\n\nFGF14 (fibroblast growth factor 14) is an intracellular FGF that modulates neuronal excitability and is expressed in the nervous system. FGFR1 (fibroblast growth factor receptor 1), while not directly in the list, is a key receptor for FGF signaling in brain development and glioma progression; the presence of multiple FGF pathway regulators suggests that FGF signaling may be dysregulated in these astrocytomas. Neurotrophic signaling often converges on PI3K-Akt-mTOR and MAPK/ERK pathways to promote survival and growth, pathways that are dysregulated in most high-grade astrocytomas.\n\n## Chromatin Remodeling and Epigenetic Program\n\nEpigenetic dysregulation is a hallmark of cancer, with alterations in DNA methylation, histone modifications, and chromatin accessibility driving oncogenic gene expression patterns. The input list contains several genes implicated in chromatin remodeling and epigenetic regulation: ATOH1 (atonal bHLH transcription factor 1), which regulates neuronal differentiation; EVI5 (ecotropic viral integration site 5), a centrosome-associated protein that may influence chromatin organization; and L3MBTL4 (lethal 3-like MBT repeat-containing 4), which is involved in chromatin compaction. While ATRX (ATRX chromatin remodeler), a critical gene in astrocytoma pathogenesis, is not in the input list, its mention in the search results[33][54] highlights the importance of chromatin dysregulation in these tumors.\n\nIDH mutations, the most common molecular alteration in lower-grade gliomas and IDH-mutant astrocytomas, drive global changes in DNA methylation through altered 2-ketoglutarate-dependent TET enzyme function, resulting in an IDH-mutant CpG island methylator phenotype (G-CIMP). The astrocytoma metabolic program, combined with altered chromatin states, is expected to promote aberrant gene expression patterns that support transformation and invasion.\n\n## Non-Coding RNA Regulatory Program\n\nA substantial portion of the input gene list comprises long non-coding RNAs (lncRNAs) and other non-coding transcripts: MIR4435-2HG, CHRM3-AS2, ADAMTS9-AS1, HMGA2-AS1, PCDH9-AS2, GNG12-AS1, LINC02742, LINC01138, LINC01798, LINC00266-1, and AC-prefixed sequences representing unannotated or novel transcripts. Long non-coding RNAs regulate gene expression at multiple levels, including transcriptional regulation through chromatin remodeling, post-transcriptional splicing and stability, and miRNA sponging. The specific roles of many lncRNAs in astrocytoma are not yet fully characterized, but evidence indicates that dysregulation of lncRNA expression contributes to glioma progression.\n\nMIR4435-2HG is a lncRNA with known roles in cancer; ADAMTS9-AS1, an antisense lncRNA to ADAMTS9, may regulate the expression of this ECM protease. In Alzheimer's disease gene co-expression network analysis, multiple lncRNAs were identified as AD-specific hub genes annotated to cytoskeleton organization, mitochondrial function, and neurogenesis[9]. Given the overlaps between Alzheimer's disease and astrocytoma transcriptomes (particularly in chronic injury states), dysregulation of these lncRNAs in astrocytomas may similarly influence cytoskeletal remodeling and metabolic function. Long non-coding RNAs and other regulatory RNAs are increasingly recognized as critical controllers of cancer cell phenotypes and therapeutic resistance.\n\n## Conclusion: Integrating Gene Programs in Astrocytoma Pathogenesis\n\nThe 170 genes provided constitute a remarkably comprehensive molecular signature spanning eleven distinct biological programs that collectively orchestrate the transformation, invasion, metabolic reprogramming, and neural interaction phenotypes characteristic of astrocytomas. No single program operates in isolation; rather, they interact through multiple regulatory nodes and feedback loops to shape the overall phenotype of neoplastic astrocytes. For example, integrin signaling (adhesion program) converges with Rho GTPase signaling (cytoskeletal program) to control cell migration and invasion. Kinase signaling (proliferation program) integrates with calcium signaling and transcriptional regulation to control both cell cycle progression and differentiation state. Metabolic reprogramming (metabolic program) provides the energetic and biosynthetic substrate for rapid growth while adapting to brain-specific constraints. Synaptic protein dysregulation (neuron-tumor interaction program) enables extensive crosstalk with the neuronal microenvironment, promoting seizures, neuroinflammation, and potentially drug resistance.\n\nThe dysregulation of negative feedback regulators (RGS, Sprouty, Spred proteins) combined with activation of kinase cascades creates a permissive environment for sustained proliferation and migration. Dedifferentiation through altered transcriptional programs preserves stemness and self-renewal capacity. Invasion is enabled through coordinated ECM remodeling, adhesion modulation, and Rho-mediated cytoskeletal dynamics. Metabolic switching provides the bioenergetic demands of rapid growth. Neuronal interactions create a permissive microenvironment and may serve as a source of growth-promoting signals.\n\nUnderstanding astrocytomas as a coordinated dysregulation of these gene programs, rather than isolated gene mutations, provides a more mechanistically complete picture of transformation and progression. Therapeutic interventions targeting single pathways have generally proven insufficient in glioma; a systems perspective incorporating multiple gene programs may yield more effective multi-pronged therapeutic strategies. The JSON output below encodes these programs and their supporting evidence in a structured format for computational analysis and integration with other data modalities.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocyte\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Brain\"\n  },\n  \"input_genes\": [\n    \"CAMK2D\",\n    \"MIR4435-2HG\",\n    \"CDK6\",\n    \"CYTOR\",\n    \"CHRM3\",\n    \"RGS6\",\n    \"KIAA1211L\",\n    \"KLHL4\",\n    \"CDH2\",\n    \"HIVEP3\",\n    \"SPRY4\",\n    \"TRIO\",\n    \"ADAMTS9\",\n    \"WWTR1\",\n    \"SPRED2\",\n    \"VAV3\",\n    \"PLAT\",\n    \"SATB2\",\n    \"CHRM3-AS2\",\n    \"SIPA1L1\",\n    \"GAP43\",\n    \"KCNIP1\",\n    \"PCNX2\",\n    \"GRIA3\",\n    \"ILDR2\",\n    \"IL1RAP\",\n    \"AC092691.1\",\n    \"CPNE4\",\n    \"IQGAP2\",\n    \"BCAT1\",\n    \"TRIM9\",\n    \"LRATD1\",\n    \"NOVA1\",\n    \"METTL7B\",\n    \"JAG1\",\n    \"DENND2A\",\n    \"PALM2-AKAP2\",\n    \"SPRED1\",\n    \"NRCAM\",\n    \"FREM2\",\n    \"DPF3\",\n    \"SPATA6\",\n    \"CNKSR2\",\n    \"HS2ST1\",\n    \"TNFRSF12A\",\n    \"GLDC\",\n    \"MYO16\",\n    \"CHL1\",\n    \"CDK14\",\n    \"CDH4\",\n    \"NEK6\",\n    \"STK17A\",\n    \"STK32A\",\n    \"STK32B\",\n    \"MED12L\",\n    \"CAMK2B\",\n    \"ARHGEF26\",\n    \"ARSJ\",\n    \"C6ORF141\",\n    \"GALR1\",\n    \"PTPRZ1\",\n    \"SH3PXD2B\",\n    \"RHOJ\",\n    \"SHROOM3\",\n    \"ITGB8\",\n    \"CREB5\",\n    \"AC092958.1\",\n    \"INSYN2A\",\n    \"LYST\",\n    \"CSMD2\",\n    \"ITGA3\",\n    \"ITGA7\",\n    \"KLHL29\",\n    \"AC124254.2\",\n    \"DPP6\",\n    \"KANK1\",\n    \"ZDHHC14\",\n    \"PREX1\",\n    \"P2RY14\",\n    \"AC004828.2\",\n    \"SLC35F1\",\n    \"CPNE8\",\n    \"TANC1\",\n    \"IGF2BP2\",\n    \"EML4\",\n    \"ADAM19\",\n    \"COL22A1\",\n    \"ACSS3\",\n    \"SRPX\",\n    \"FRMD5\",\n    \"MEIS1\",\n    \"ESR2\",\n    \"SEMA5A\",\n    \"ENC1\",\n    \"SYNJ2\",\n    \"COL4A2\",\n    \"MEG8\",\n    \"SEMA3E\",\n    \"MAP3K1\",\n    \"POSTN\",\n    \"DLC1\",\n    \"DNMBP\",\n    \"ETV5\",\n    \"DEC1\",\n    \"ABCC3\",\n    \"LONRF2\",\n    \"CEMIP\",\n    \"LINC02742\",\n    \"SHISA9\",\n    \"ETV6\",\n    \"MAMLD1\",\n    \"ERI1\",\n    \"FGF14\",\n    \"SNTG1\",\n    \"FNDC3B\",\n    \"CLMN\",\n    \"SPRY2\",\n    \"PRAG1\",\n    \"SLC8A1\",\n    \"LSAMP\",\n    \"LMO2\",\n    \"DNM1\",\n    \"PDE8A\",\n    \"AC087564.1\",\n    \"GRIK2\",\n    \"RCAN1\",\n    \"GRIN2B\",\n    \"ALK\",\n    \"VMP1\",\n    \"AL356124.1\",\n    \"LEF1\",\n    \"HMGA2\",\n    \"HMGA2-AS1\",\n    \"LDLRAD3\",\n    \"IGF2BP3\",\n    \"PCDH7\",\n    \"LAMC1\",\n    \"PCDH9-AS2\",\n    \"TRPM3\",\n    \"ACSBG1\",\n    \"NES\",\n    \"ADGRL3\",\n    \"ADAM12\",\n    \"HS3ST5\",\n    \"ADAMTS9-AS1\",\n    \"MTCL1\",\n    \"UBASH3B\",\n    \"ARHGAP26\",\n    \"RASSF8\",\n    \"AC017002.5\",\n    \"PGAP1\",\n    \"LIMK1\",\n    \"RYR3\",\n    \"AC060834.2\",\n    \"ZMAT4\",\n    \"KCNMA1\",\n    \"SCD5\",\n    \"SAMD4A\",\n    \"RUNX1\",\n    \"NPAS3\",\n    \"AC064875.1\",\n    \"SCG2\",\n    \"GAS2\",\n    \"OSBP2\",\n    \"PDGFA\",\n    \"LAMA4\",\n    \"SLC35F4\",\n    \"EMP1\",\n    \"KCND2\",\n    \"DPYSL5\",\n    \"RFFL\",\n    \"KALRN\",\n    \"ITPR2\",\n    \"LAMA2\",\n    \"SLC1A2\",\n    \"ELOVL2\",\n    \"L3MBTL4\",\n    \"DPY19L1\",\n    \"RBPMS\",\n    \"RGS17\",\n    \"LPAR1\",\n    \"DUSP6\",\n    \"LINC01138\",\n    \"RNF157\",\n    \"PXYLP1\",\n    \"LHFPL6\",\n    \"FBN2\",\n    \"RUBCNL\",\n    \"FGFR1\",\n    \"SH3KBP1\",\n    \"GRB10\",\n    \"GPR158\",\n    \"LINC01798\",\n    \"EPHA3\",\n    \"PTPRJ\",\n    \"GNG12-AS1\",\n    \"PRKD1\",\n    \"PVT1\",\n    \"LINC00266-1\",\n    \"SEMA3A\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Integrin-Mediated Cell Adhesion and Mechanotransduction\",\n      \"description\": \"This program orchestrates cellular interactions with the extracellular matrix and neighboring cells through integrin heterodimers, focal adhesion complexes, and downstream mechanotransduction signaling. Integrin alpha and beta subunits form heterodimeric complexes that bind extracellular matrix ligands (collagen, laminin, fibronectin) and transduce mechanical tension into biochemical signals that control cell migration, invasion, and gene expression through FAK and YAP/TAZ signaling. Talin proteins directly link integrins to the actin cytoskeleton and sense mechanical forces. Laminin and collagen chains serve as primary ECM ligands. This program is dysregulated in astrocytomas to promote invasion through tumor-infiltrated brain parenchyma and blood vessels.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Integrin-mediated cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Describes talin-integrin-actin linkage and mechanotransduction, including paxillin phosphorylation and YAP/TAZ nuclear translocation downstream of integrin signaling\"\n            }\n          ],\n          \"genes\": [\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ITGB8\",\n            \"LAMC1\",\n            \"LAMA2\",\n            \"LAMA4\",\n            \"LIMK1\"\n          ]\n        },\n        {\n          \"name\": \"Focal adhesion assembly and turnover\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Discusses FAK activation through paxillin Y118 phosphorylation and focal adhesion complex dynamics\"\n            }\n          ],\n          \"genes\": [\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ITGB8\",\n            \"LIMK1\",\n            \"ARHGAP26\"\n          ]\n        },\n        {\n          \"name\": \"Mechanotransduction and YAP signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"YAP translocation to nucleus as downstream mechanotransduction output regulated by talin rod domain and FAK signaling\"\n            }\n          ],\n          \"genes\": [\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ITGB8\",\n            \"WWTR1\",\n            \"LIMK1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Integrin heterodimers\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Integrin heterodimers consisting of alpha and beta subunits activate in response to mechanical tension through talin binding\"\n            }\n          ],\n          \"genes\": [\n            \"ITGA3\",\n            \"ITGA7\",\n            \"ITGB8\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix scaffolds\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Laminin and collagen components of basement membrane and ECM that serve as integrin ligands\"\n            }\n          ],\n          \"genes\": [\n            \"LAMC1\",\n            \"LAMA2\",\n            \"LAMA4\",\n            \"COL4A2\",\n            \"COL22A1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced focal adhesion assembly and stability in response to ECM stiffness\",\n        \"Increased cell migration velocity and invasive capacity\",\n        \"Mechanically-dependent YAP/TAZ nuclear localization and growth-promoting gene expression\",\n        \"Sustained cell-matrix adhesion enabling invasion through restrictive brain parenchyma\"\n      ],\n      \"evidence_summary\": \"Integrin-mediated mechanotransduction is a critical regulator of cancer cell migration and invasion. The input list contains multiple components of the integrin signaling cascade and ECM composition, suggesting coordinated dysregulation of cell adhesion in astrocytomas. High-grade gliomas exhibit enhanced expression of alpha-3 and alpha-7 integrins and their ligands, enabling invasion. Mechanotransduction through integrin signaling controls FAK activation and YAP nuclear translocation, both pro-tumoral outputs. The presence of multiple ECM component genes (laminin, collagen) alongside integrin subunits and signaling effectors suggests that astrocytomas coordinate cell-autonomous integrin signaling with remodeling of the ECM niche to support invasion and establish supportive microenvironments.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"56\",\n          \"notes\": \"Primary source demonstrating talin force coupling, FAK-paxillin signaling, and YAP translocation downstream of integrin-talin-actin complexes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ITGA3\",\n        \"ITGA7\",\n        \"ITGB8\",\n        \"LAMC1\",\n        \"LAMA2\",\n        \"LAMA4\",\n        \"COL4A2\",\n        \"COL22A1\",\n        \"LIMK1\",\n        \"ARHGAP26\",\n        \"WWTR1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"FAK\",\n          \"Src\",\n          \"Paxillin\",\n          \"Talin\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"56\",\n            \"notes\": \"FAK, Src-family kinases, paxillin, and talin proteins are essential focal adhesion components not present in input list but required for integrin mechanotransduction\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Rho GTPase Signaling and Actin Dynamics\",\n      \"description\": \"The Rho GTPase signaling program controls actin cytoskeleton dynamics, cell migration, and invasion through a sophisticated network of GEFs (guanine nucleotide exchange factors), GAPs (GTPase-activating proteins), and downstream effectors. RhoA, Rac1, and Cdc42 function as molecular switches toggling between active GTP-bound and inactive GDP-bound states. GEFs promote activation by catalyzing GDP-to-GTP exchange. GAPs inactivate GTPases through GTP hydrolysis. Negative feedback regulators (RGS, Sprouty, Spred) suppress Rho activation downstream of growth factor receptors. Enhanced Rho signaling drives stress fiber formation, cell contractility, and invasion in astrocytomas.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"RhoA activation and stress fiber formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"ROCK1 pathway controls stress fiber formation and cell contractility downstream of RhoA activation, implicated in glioma cell migration and invasion\"\n            }\n          ],\n          \"genes\": [\n            \"RHOJ\",\n            \"ARHGEF26\",\n            \"TRIO\",\n            \"DLC1\",\n            \"ARHGAP26\",\n            \"SIPA1L1\",\n            \"VAV3\",\n            \"LIMK1\"\n          ]\n        },\n        {\n          \"name\": \"Rac1 and Cdc42 activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"SDF-1alpha stimulates CXCR4/PI3K/Rac1 pathway affecting actin dynamics and endothelial permeability; high Rac-1 expression promoted cell migration\"\n            }\n          ],\n          \"genes\": [\n            \"VAV3\",\n            \"TRIO\",\n            \"PREX1\",\n            \"ARHGAP26\"\n          ]\n        },\n        {\n          \"name\": \"Negative feedback suppression of Rho signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"SPRY2 regulates ERK-MAPK signaling through miR-21-mediated mechanism; sprouty and spred proteins suppress RTK signaling that activates Rho pathways\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"MYB regulates SPRY2 transcription as negative feedback on MAPK signaling\"\n            }\n          ],\n          \"genes\": [\n            \"SPRY4\",\n            \"SPRY2\",\n            \"SPRED2\",\n            \"SPRED1\",\n            \"RGS6\",\n            \"RGS17\",\n            \"DUSP6\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Rho GTPase exchange factors\",\n          \"citations\": [\n            {\n              \"source_id\": \"7\",\n              \"notes\": \"GEFs catalyze GDP-to-GTP exchange to activate Rho family GTPases\"\n            }\n          ],\n          \"genes\": [\n            \"ARHGEF26\",\n            \"TRIO\",\n            \"VAV3\",\n            \"PREX1\"\n          ]\n        },\n        {\n          \"name\": \"Rho GTPase-activating proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"DLC1 SAM domain-binding peptides inhibit cancer cell migration by inactivating RhoA through GAP activity\"\n            }\n          ],\n          \"genes\": [\n            \"DLC1\",\n            \"ARHGAP26\",\n            \"SIPA1L1\"\n          ]\n        },\n        {\n          \"name\": \"Actin-binding and cytoskeletal regulators\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Actin polymerization controlled by cofilin phosphorylation via LIMK and downstream Rho signaling\"\n            }\n          ],\n          \"genes\": [\n            \"LIMK1\",\n            \"SHROOM3\",\n            \"TRIM9\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Uncontrolled RhoA activation driving excessive stress fiber formation and contractility\",\n        \"Enhanced cell migration velocity and invasion through ECM\",\n        \"Suppressed negative feedback through RGS and Sprouty downregulation or mutation\",\n        \"Dysregulated Rac1/Cdc42 signaling affecting cellular protrusions and directional migration\"\n      ],\n      \"evidence_summary\": \"Rho GTPase signaling is dysregulated in high-grade gliomas to promote migration and invasion. The input list contains multiple GEFs, GAPs, and negative feedback regulators, suggesting a complex regulatory landscape where pro-migration signals (GEFs) may overcome inhibitory signals (GAPs, RGS proteins). Silencing of Drp1 inhibits glioma proliferation and invasion through RHOA/ROCK1 pathway suppression, directly implicating Rho signaling in astrocytoma progression. The presence of multiple negative feedback regulators (RGS, Sprouty, Spred, DUSP6) suggests that dysregulation of these brakes—either through downregulation or mutation—represents a key event in astrocytoma transformation. Enhanced Rho signaling promotes stress fiber formation, cell contractility, and invasion-permissive morphologies.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"Silencing Drp1 inhibits glioma proliferation and invasion via RHOA/ROCK1 pathway\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"DLC1 inactivates RhoA to inhibit cancer cell migration\"\n        },\n        {\n          \"source_id\": \"7\",\n          \"notes\": \"Rac1 pathway activated by CXCR4 signaling affects actin dynamics\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"RHOJ\",\n        \"ARHGEF26\",\n        \"TRIO\",\n        \"DLC1\",\n        \"ARHGAP26\",\n        \"SIPA1L1\",\n        \"VAV3\",\n        \"SPRY4\",\n        \"SPRY2\",\n        \"SPRED2\",\n        \"SPRED1\",\n        \"RGS6\",\n        \"RGS17\",\n        \"DUSP6\",\n        \"LIMK1\",\n        \"SHROOM3\",\n        \"TRIM9\",\n        \"PREX1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ROCK1\",\n          \"PAK\",\n          \"Cofilin\",\n          \"Paxillin\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"34\",\n            \"notes\": \"ROCK1 is the major effector of RhoA-mediated stress fiber formation, essential for the Rho-ROCK pathway in glioma invasion\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Kinase Signaling Cascades and Cell Cycle Progression\",\n      \"description\": \"The kinase signaling program encompasses cyclin-dependent kinases (CDKs), mitogen-activated protein kinases, calcium/calmodulin-dependent kinases, and receptor tyrosine kinases that collectively control cell cycle progression, survival, proliferation, and differentiation. CDK6 drives G1-to-S phase transition when activated by cyclin D complexes. Calcium-dependent kinases (CAMK2B, CAMK2D) integrate calcium signals to control gene expression and metabolism. Serine-threonine kinases (STK family members) participate in diverse signaling cascades. ALK, a receptor tyrosine kinase, when dysregulated through fusion or amplification, drives constitutive kinase signaling. MAP3K1 sits upstream of MAPK/ERK and JNK cascades. These kinases are frequently dysregulated in astrocytomas to promote uncontrolled proliferation and survival.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"G1-to-S phase transition\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"CDK6 controls G1-to-S phase transition; cyclin-CDK complexes are frequently dysregulated in cancer\"\n            }\n          ],\n          \"genes\": [\n            \"CDK6\",\n            \"CDK14\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-dependent signaling and plasticity\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"GLUT3 neuronal activity-dependent plasma translocation regulated by PKCε phosphorylation of T232 and S246; PKCε is a calcium-dependent kinase\"\n            }\n          ],\n          \"genes\": [\n            \"CAMK2B\",\n            \"CAMK2D\",\n            \"TRPM3\",\n            \"GRIN2B\",\n            \"GRIA3\"\n          ]\n        },\n        {\n          \"name\": \"Receptor tyrosine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"EML4-ALK fusion drives cellular senescence in normal cells and anchorage-independent growth in immortalized cells; ALK promotes MAPK and PI3K pathway activation\"\n            }\n          ],\n          \"genes\": [\n            \"ALK\",\n            \"FGFR1\",\n            \"MAP3K1\"\n          ]\n        },\n        {\n          \"name\": \"PI3K-Akt-mTOR pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"KRAS gene silencing inhibits PI3K-Akt-mTOR signaling to regulate breast cancer cell proliferation, EMT, and invasion; this pathway is central to cancer biology\"\n            }\n          ],\n          \"genes\": [\n            \"PREX1\",\n            \"MAP3K1\",\n            \"STK17A\",\n            \"STK32A\",\n            \"STK32B\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Cyclin-CDK complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"5\",\n              \"notes\": \"CDKs form catalytic cores of cell cycle checkpoints\"\n            }\n          ],\n          \"genes\": [\n            \"CDK6\",\n            \"CDK14\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-calmodulin signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Calcium-calmodulin-dependent protein kinases integrate calcium signals\"\n            }\n          ],\n          \"genes\": [\n            \"CAMK2B\",\n            \"CAMK2D\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Accelerated cell cycle progression through G1-S checkpoint\",\n        \"Enhanced survival signaling through PI3K-Akt-mTOR pathway\",\n        \"Dysregulation of MAPK/ERK signaling downstream of kinase activation\",\n        \"Altered calcium signaling affecting metabolism, migration, and differentiation\",\n        \"Constitutive ALK signaling (if dysregulated) driving proliferation and transformation\"\n      ],\n      \"evidence_summary\": \"Kinase dysregulation is a hallmark of astrocytoma and other cancers. CDK6 is frequently amplified in high-grade gliomas, driving aberrant G1-S progression. CAMK-dependent signaling integrates calcium influx through NMDA and AMPA glutamate receptors (themselves dysregulated in gliomas) to drive proliferation and migration. ALK fusion events, while more common in lung cancers and lymphomas, have been reported in neural tumors and drive constitutive MAPK and PI3K pathway activation. MAP3K1 sits upstream of multiple effector kinases, integrating growth factor and stress signals. The presence of multiple kinases in the input list suggests that astrocytomas employ multiple redundant pathways to overcome cell cycle checkpoints and survival constraints, a common mechanism of cancer progression.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"KRAS-mediated PI3K-Akt-mTOR signaling controls cancer proliferation\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"ALK-mediated transformation drives both senescence and growth depending on cellular context\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"CAMK-mediated signaling in neuronal context\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CDK6\",\n        \"CDK14\",\n        \"CAMK2B\",\n        \"CAMK2D\",\n        \"STK17A\",\n        \"STK32A\",\n        \"STK32B\",\n        \"NEK6\",\n        \"ALK\",\n        \"MAP3K1\",\n        \"PREX1\",\n        \"FGFR1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"Cyclin D1\",\n          \"Cyclin D2\",\n          \"FAK\",\n          \"ERK1/2\",\n          \"Akt\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"13\",\n            \"notes\": \"Cyclin-CDK and Akt are essential components of proliferation pathways often dysregulated in cancer\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"MAPK/ERK Feedback Suppression and Pathway Regulation\",\n      \"description\": \"The MAPK/ERK pathway represents one of the central growth-promoting cascades in cancer, driving proliferation, survival, and differentiation. However, this pathway is subject to extensive negative feedback regulation through multiple mechanisms. The input list contains four key negative regulators: SPRY2, SPRY4, SPRED1, and SPRED2, collectively termed sprouty and spred proteins; and DUSP6, a dual-specificity phosphatase that directly dephosphorylates ERK1/2. These negative feedback regulators suppress MAPK/ERK signaling in response to growth factors and stress signals. Dysregulation of these suppressors—through loss of expression, mutations, or epigenetic silencing—combined with upstream kinase activation, creates a permissive environment for sustained MAPK signaling in astrocytomas.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"MAPK/ERK pathway suppression\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"SPRY2 regulates ERK-MAPK signaling pathway through miR-21-mediated mechanism during differentiation\"\n            },\n            {\n              \"source_id\": \"58\",\n              \"notes\": \"SPRY2 is a novel unfolded protein response regulator that may suppress MAPK signaling\"\n            }\n          ],\n          \"genes\": [\n            \"SPRY2\",\n            \"SPRY4\",\n            \"SPRED1\",\n            \"SPRED2\",\n            \"DUSP6\"\n          ]\n        },\n        {\n          \"name\": \"RTK signaling antagonism\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"Sprouty proteins antagonize RTK signaling through multiple mechanisms including Grb2 sequestration\"\n            }\n          ],\n          \"genes\": [\n            \"SPRY2\",\n            \"SPRY4\",\n            \"SPRED1\",\n            \"SPRED2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Phosphatase complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"DUSP6 is a dual-specificity phosphatase that directly inactivates ERK1/2\"\n            }\n          ],\n          \"genes\": [\n            \"DUSP6\"\n          ]\n        },\n        {\n          \"name\": \"Negative feedback regulator complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"Sprouty proteins form signaling complexes that suppress RTK-mediated signaling\"\n            }\n          ],\n          \"genes\": [\n            \"SPRY2\",\n            \"SPRY4\",\n            \"SPRED1\",\n            \"SPRED2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Loss or reduction of MAPK/ERK negative feedback allows sustained signaling\",\n        \"Enhanced proliferation and survival downstream of MAPK/ERK\",\n        \"Increased transcription of proliferation-associated genes (c-MYC, cyclin D1, etc.)\",\n        \"Altered differentiation status favoring undifferentiated or progenitor-like phenotypes\",\n        \"Potential vulnerability to MAPK pathway inhibitors if suppressor downregulation is the primary defect\"\n      ],\n      \"evidence_summary\": \"The presence of multiple MAPK/ERK negative feedback regulators in the input list is striking and suggests that dysregulation of these suppressors represents a key event in astrocytoma pathogenesis. In normal cells, MAPK/ERK signaling triggers negative feedback through sprouty and DUSP upregulation, establishing a 'toggle switch' that prevents excessive signaling. In astrocytomas, downregulation or loss of these suppressors (which can occur through mutations, epigenetic silencing, or transcriptional dysregulation) would allow sustained MAPK signaling even in the absence of continuous growth factor stimulation. This mechanism is complementary to upstream kinase activation (through RAS mutations, BRAF mutations, or RTK amplification) and together they create a robust, redundantly-controlled permissive environment for proliferation.\",\n      \"significance_score\": 0.71,\n      \"citations\": [\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"SPRY2 regulates MAPK signaling through RTK pathway antagonism\"\n        },\n        {\n          \"source_id\": \"58\",\n          \"notes\": \"MYB directly regulates SPRY2 transcription as negative feedback on MAPK\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SPRY2\",\n        \"SPRY4\",\n        \"SPRED1\",\n        \"SPRED2\",\n        \"DUSP6\",\n        \"RGS6\",\n        \"RGS17\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ERK1\",\n          \"ERK2\",\n          \"MEK1\",\n          \"MEK2\",\n          \"RAF\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"55\",\n            \"notes\": \"ERK and MEK are essential components of the MAPK cascade regulated by feedback suppressors\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Calcium Signaling and Ion Homeostasis\",\n      \"description\": \"Calcium signaling represents a fundamental communication mechanism in astrocytes, coupling extracellular and intracellular signals to control gene expression, metabolism, migration, and neuron-astrocyte interactions. The input list contains multiple calcium signaling components: inositol 1,4,5-trisphosphate receptors (ITPR2), ryanodine receptors (RYR3), voltage-gated calcium and potassium channels (TRPM3, KCNMA1, KCND2), glutamate receptors that gate calcium influx (GRIN2B, GRIA3, GRIK2), and calcium/calmodulin-dependent kinases (CAMK2B, CAMK2D). Dysregulation of calcium signaling in astrocytomas promotes metabolic reprogramming, migration, and aberrant neuron-tumor interactions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"ER calcium release and IP3 signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"ITPR2-mediated calcium release from ER leads to mitochondrial calcium uptake via MCU during stress, causing accumulation and reduced ΔΨm; ITPR2 knockdown prevents senescence induction\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Chronic hyperglycemia disrupts neuronal function through intracellular calcium imbalance and ER stress\"\n            }\n          ],\n          \"genes\": [\n            \"ITPR2\"\n          ]\n        },\n        {\n          \"name\": \"Mitochondrial calcium handling\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"Calcium accumulation in mitochondrial matrix activates permeability transition pore (mPTP), causing collapse of ΔΨm and ROS production\"\n            }\n          ],\n          \"genes\": [\n            \"ITPR2\",\n            \"RYR3\"\n          ]\n        },\n        {\n          \"name\": \"Glutamate receptor-mediated calcium influx\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Glioma-derived glutamate acting through neuronal NMDA and AMPA receptors alters neuronal excitability; tumor cells with aberrant glutamate receptor expression may dysregulate calcium\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\",\n            \"GRIA3\",\n            \"GRIK2\"\n          ]\n        },\n        {\n          \"name\": \"GPCR-mediated calcium signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Muscarinic M1 receptor mediates cholinergic regulation and calcium signaling in hippocampus\"\n            }\n          ],\n          \"genes\": [\n            \"CHRM3\",\n            \"P2RY14\"\n          ]\n        },\n        {\n          \"name\": \"Calcium-dependent gene expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"PKCε phosphorylates GLUT3 in calcium-dependent manner to regulate neuronal glucose uptake; CAMK kinases integrate calcium signals for gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"CAMK2B\",\n            \"CAMK2D\",\n            \"CREB5\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Endoplasmic reticulum calcium channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"ITPR2 is a calcium channel at ER and MERCS (mitochondria-ER contact sites)\"\n            }\n          ],\n          \"genes\": [\n            \"ITPR2\"\n          ]\n        },\n        {\n          \"name\": \"Ryanodine receptor calcium channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"RYR3 is a calcium-release channel in ER, related to ryanodine receptors\"\n            }\n          ],\n          \"genes\": [\n            \"RYR3\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated ion channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Voltage-gated calcium and potassium channels regulate cellular excitability and calcium homeostasis\"\n            }\n          ],\n          \"genes\": [\n            \"TRPM3\",\n            \"KCNMA1\",\n            \"KCND2\"\n          ]\n        },\n        {\n          \"name\": \"Ligand-gated glutamate receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"NMDA and AMPA receptors gate calcium influx in response to synaptic glutamate\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\",\n            \"GRIA3\",\n            \"GRIK2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated intracellular calcium homeostasis promoting mitochondrial dysfunction\",\n        \"Altered calcium-dependent gene expression through CAMK and CREB pathways\",\n        \"Enhanced migration through calcium-dependent cytoskeletal remodeling\",\n        \"Aberrant calcium signaling promoting metabolic reprogramming\",\n        \"Aberrant neuron-astrocyte calcium coupling promoting seizures and peritumoral neuronal dysfunction\"\n      ],\n      \"evidence_summary\": \"Calcium signaling is fundamentally dysregulated in astrocytomas. ITPR2, a key component of ER calcium release, drives mitochondrial calcium accumulation and mitochondrial permeability transition pore activation, leading to reduced mitochondrial membrane potential, ROS production, and cell dysfunction. In the context of cancer, dysregulation of calcium signaling can promote metabolic reprogramming (particularly toward glycolysis), affect survival signaling, and enhance migration. The presence of glutamate receptor subunits in astrocytomas is particularly striking, as it suggests that tumor cells may directly respond to synaptic glutamate or even express and release glutamate themselves, creating aberrant calcium-dependent signaling that affects both tumor cells and neighboring neurons. Recent evidence demonstrates that astrocytic mitochondrial connexin-43 directly regulates IDH3α to maintain glycolytic metabolism and lactate production for neuronal energy supply; dysregulation of this coupling in astrocytomas would promote metabolic reprogramming. The calcium signaling program is therefore predicted to promote metabolic reprogramming, migration, and pathological neuron-tumor interactions.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"21\",\n          \"notes\": \"ITPR2-mediated calcium signaling and mitochondrial dysfunction in cellular senescence\"\n        },\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"Glioma-derived glutamate acting through neuronal receptors and aberrant astrocyte calcium signaling\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"Astrocytic mitochondrial Cx43 regulates IDH3α and metabolic coupling to neurons\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ITPR2\",\n        \"RYR3\",\n        \"TRPM3\",\n        \"KCNMA1\",\n        \"KCND2\",\n        \"GRIN2B\",\n        \"GRIA3\",\n        \"GRIK2\",\n        \"CHRM3\",\n        \"P2RY14\",\n        \"CAMK2B\",\n        \"CAMK2D\",\n        \"CREB5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MCU\",\n          \"NCX\",\n          \"PMCA\",\n          \"STIM1\",\n          \"Connexin-43\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"21\",\n            \"notes\": \"MCU (mitochondrial calcium uniporter) is essential for mitochondrial calcium uptake; NCX and PMCA are calcium exchangers; STIM1 couples ER calcium depletion to store-operated calcium entry\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic Plasticity and Neuron-Tumor Interaction\",\n      \"description\": \"A substantial subset of the input gene list encodes proteins classically associated with synaptic function, synaptic plasticity, and neuron-astrocyte interactions. These include growth-associated protein 43 (GAP43), synaptojanin-2 (SYNJ2), neuronal cell adhesion molecules (NRCAM, CHL1, LSAMP), glutamate receptors (GRIA3, GRIN2B, GRIK2), and related signaling proteins. The presence of these synaptic genes in astrocytomas is striking and suggests either that tumors retain developmental neural programs or that they actively dysregulate synaptic genes to manipulate the neuronal microenvironment. High-grade gliomas promote seizures and neuronal dysfunction in peritumoral regions, effects mediated through aberrant astrocyte-neuron communication.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synaptic plasticity and axonal growth\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"GAP43 expression pattern correlates with regenerative capacity; reduced expression in Parkinson's disease suggests impaired neuronal growth\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"GAP-43 plays central role in axonal growth and plasticity; promotes neural regeneration and repair\"\n            }\n          ],\n          \"genes\": [\n            \"GAP43\",\n            \"SYNJ2\",\n            \"DPP6\"\n          ]\n        },\n        {\n          \"name\": \"Glutamate receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Glioma cells cause elevation of local glutamate concentration and alter neuronal excitability via xCT transporter and glutamate receptor activation; astrocytic synaptogenic factors linked to tumor-associated seizures\"\n            }\n          ],\n          \"genes\": [\n            \"GRIN2B\",\n            \"GRIA3\",\n            \"GRIK2\",\n            \"SLC1A2\"\n          ]\n        },\n        {\n          \"name\": \"Cell-cell adhesion and neuron-astrocyte interaction\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Genes involved in neuron-astrocyte interactions (Il33, Clasp2, Fgfr2) significantly upregulated in chronic TBI; NRCAM and CHL1 mediate axon-axon and axon-glia interactions\"\n            }\n          ],\n          \"genes\": [\n            \"NRCAM\",\n            \"CHL1\",\n            \"LSAMP\",\n            \"CDH2\",\n            \"CDH4\",\n            \"JAG1\"\n          ]\n        },\n        {\n          \"name\": \"Synaptic organization and neuromodulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"Astrocytes mediate cholinergic regulation of neural function through M1 muscarinic receptor; CHRM3-mediated signaling modulates hippocampal neurogenesis and memory\"\n            }\n          ],\n          \"genes\": [\n            \"CHRM3\",\n            \"P2RY14\",\n            \"DENND2A\",\n            \"CPNE4\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Synaptic terminals and presynaptic machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Synaptic terminals release glutamate; astrocytes surrounding synapses regulate neurotransmitter reuptake and gliotransmitter release\"\n            }\n          ],\n          \"genes\": [\n            \"SYNJ2\",\n            \"SLC1A2\",\n            \"GRIA3\",\n            \"GRIN2B\"\n          ]\n        },\n        {\n          \"name\": \"Cell adhesion molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"CAMs mediate cell-cell interactions between neurons and astrocytes; dysregulation affects synaptic connectivity\"\n            }\n          ],\n          \"genes\": [\n            \"NRCAM\",\n            \"CHL1\",\n            \"LSAMP\",\n            \"CDH2\",\n            \"CDH4\"\n          ]\n        },\n        {\n          \"name\": \"Growth cone structure\",\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"GAP43 is localized to growth cones where it regulates axonal extension\"\n            }\n          ],\n          \"genes\": [\n            \"GAP43\",\n            \"DPYSL5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tumor-derived glutamate release affecting neuronal excitability\",\n        \"Aberrant astrocyte-neuron calcium coupling promoting seizures\",\n        \"Dysregulated synaptic plasticity in peritumoral regions\",\n        \"Altered neuronal function through aberrant cell-cell interactions\",\n        \"Impaired neuronal integrity potentially reducing anti-tumor immunity\"\n      ],\n      \"evidence_summary\": \"Recent studies have revealed that high-grade gliomas promote aberrant neuronal activity and seizures through multiple mechanisms, including glutamate dysregulation and altered astrocyte-neuron interactions. Glioma cells cause elevation of local glutamate concentration and alter neuronal excitability via the xCT transporter system and glutamate receptor activation. Furthermore, synaptogenic factors produced by specific astrocyte populations have been linked to tumor-associated seizures. The presence of glutamate receptor subunits, cell adhesion molecules, and synaptic proteins in the input astrocytoma gene list suggests that neoplastic astrocytes retain or dysregulate programs of neural development and astrocyte-neuron interaction. This dysregulation may serve tumoral functions by promoting peritumoral neuronal dysfunction, suppressing anti-tumor neuronal activity, or creating a permissive microenvironment for tumor growth. The synaptic program is therefore predicted to dramatically alter neuron-tumor crosstalk, promoting seizures, neuronal dysfunction, and a permissive neuronal microenvironment for tumor progression.\",\n      \"significance_score\": 0.77,\n      \"citations\": [\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"Glioma cells alter peritumoral neuronal excitability through glutamate dysregulation and synaptogenic factors\"\n        },\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"Genes involved in neuron-astrocyte interactions dysregulated in chronic brain injury with parallels to cancer pathology\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"GAP43 role in neural regeneration and plasticity\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"GAP43\",\n        \"SYNJ2\",\n        \"NRCAM\",\n        \"CHL1\",\n        \"LSAMP\",\n        \"GRIA3\",\n        \"GRIN2B\",\n        \"GRIK2\",\n        \"CDH2\",\n        \"CDH4\",\n        \"CHRM3\",\n        \"P2RY14\",\n        \"SLC1A2\",\n        \"JAG1\",\n        \"DPP6\",\n        \"DENND2A\",\n        \"CPNE4\",\n        \"DPYSL5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PSD95\",\n          \"SynGAP\",\n          \"NMDAR\",\n          \"AMPAR\",\n          \"Synapsin\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"42\",\n            \"notes\": \"PSD95 and other synaptic scaffold proteins are essential for glutamate receptor signaling and synaptic plasticity\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Differentiation and Stemness Control\",\n      \"description\": \"Cellular differentiation represents a fundamental axis controlling cell fate, proliferation, and self-renewal in tissue development and cancer. The input gene list contains multiple transcription factors implicated in stem cell maintenance, neural progenitor identity, and developmental decisions: SATB2 (matrix attachment region-binding protein), LEF1 (lymphoid enhancer-binding factor 1), RUNX1 (runt-related transcription factor), CREB5, LMO2 (LIM domain only 2), MEIS1 (meis homeobox 1), HMGA2 (high-mobility group AT-hook 2), NPAS3 (neuronal PAS domain protein 3), and ENC1 (ectodermal-neural cortex 1). Dysregulation of this transcriptional program is expected to maintain astrocytoma cells in a progenitor-like or stem cell state, preventing terminal differentiation and preserving proliferative capacity.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Neural stem cell maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"Flow cytometry shows increased EGFR, SOX2, and CXCR4 expression in neural stem cells including astrocyte progenitor cells after TBI; these markers suggest stem cell maintenance program\"\n            },\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"HOXA genes (regulated by KMT2A and MEIS1 cofactors) establish developmental hierarchies and stem cell maintenance in hematopoiesis; similar mechanisms likely operate in neural tissue\"\n            }\n          ],\n          \"genes\": [\n            \"MEIS1\",\n            \"LMO2\",\n            \"LEF1\",\n            \"RUNX1\"\n          ]\n        },\n        {\n          \"name\": \"Developmental transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"HOXA genes govern developmental differentiation through integrated regulatory architecture; KMT2A-dependent methylation and MEIS cofactors control lineage commitment\"\n            },\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"SATB2 acts as potent transcription factor to enhance bone cell differentiation and promote bone regeneration; matrix attachment regions regulate 3D chromatin organization\"\n            }\n          ],\n          \"genes\": [\n            \"SATB2\",\n            \"LEF1\",\n            \"RUNX1\",\n            \"MEIS1\",\n            \"LMO2\"\n          ]\n        },\n        {\n          \"name\": \"Undifferentiated and cancer stem cell phenotype\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"JAB1 promotes breast cancer stemness by stabilizing CUL4B; stemness markers (OCT4, KLF4, NANOG, c-MYC) elevated with JAB1 overexpression and reduced with knockdown\"\n            }\n          ],\n          \"genes\": [\n            \"HMGA2\",\n            \"CREB5\",\n            \"ENC1\",\n            \"NPAS3\"\n          ]\n        },\n        {\n          \"name\": \"HMGA2-mediated stemness\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"HMGA2 frequently upregulated in cancers through amplification or fusion events; drives undifferentiated and stem-like phenotypes\"\n            }\n          ],\n          \"genes\": [\n            \"HMGA2\",\n            \"HMGA2-AS1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"HOXA genes function in complexes with KMT2A, MEIS cofactors, and chromatin remodeling complexes\"\n            }\n          ],\n          \"genes\": [\n            \"MEIS1\",\n            \"LMO2\",\n            \"LEF1\",\n            \"RUNX1\",\n            \"SATB2\",\n            \"CREB5\"\n          ]\n        },\n        {\n          \"name\": \"Nuclear matrix attachment regions\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"SATB2 binds nuclear matrix attachment regions and regulates chromatin architecture and gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"SATB2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of progenitor-like phenotype with reduced terminal differentiation\",\n        \"Enhanced self-renewal and proliferative capacity\",\n        \"Preserved stemness markers (SOX2, NESTIN, OLIG2) in astrocytoma cells\",\n        \"Resistance to differentiation-inducing therapies\",\n        \"Sustained tumorigenicity and tumor-initiating capacity\"\n      ],\n      \"evidence_summary\": \"High-grade astrocytomas characteristically display reduced expression of mature astrocytic markers (GFAP, glutamine synthetase) and elevated expression of progenitor markers (nestin, SOX2, OLIG2), consistent with a block in differentiation or maintenance of progenitor identity. The input list contains multiple transcription factors known to maintain neural stem cell identity and developmental hierarchies. LEF1 is a key component of Wnt signaling essential for neural progenitor maintenance. MEIS1 and LMO2 function as cofactors for HOXA cluster genes, which establish developmental hierarchies and are frequently dysregulated in acute myeloid leukemia through KMT2A fusion events; similar mechanisms likely operate in neural development. HMGA2 is frequently upregulated in cancers through amplification or t(12;15) translocations and drives undifferentiated and stem-like phenotypes. Dysregulation of this transcriptional program would maintain astrocytoma cells in a more progenitor-like or dedifferentiated state, preventing terminal differentiation and preserving proliferative and self-renewal capacity. This represents a critical adaptation for cancer cell survival, as differentiation typically leads to proliferative arrest and specialized function rather than survival and growth.\",\n      \"significance_score\": 0.73,\n      \"citations\": [\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"HOXA genes and MEIS cofactors regulate developmental hierarchies and stem cell maintenance\"\n        },\n        {\n          \"source_id\": \"23\",\n          \"notes\": \"SATB2 regulates differentiation decisions in bone tissue\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"Stemness markers dysregulated in cancer cells\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SATB2\",\n        \"LEF1\",\n        \"RUNX1\",\n        \"CREB5\",\n        \"LMO2\",\n        \"MEIS1\",\n        \"HMGA2\",\n        \"NPAS3\",\n        \"ENC1\",\n        \"HMGA2-AS1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"OLIG2\",\n          \"SOX2\",\n          \"NESTIN\",\n          \"KMT2A\",\n          \"PRC2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"24\",\n            \"notes\": \"KMT2A and PRC2 are critical upstream regulators of HOXA gene expression in development\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling and Invasion Program\",\n      \"description\": \"Cancer cell invasion requires coordinated degradation and remodeling of the extracellular matrix through the action of proteases and their inhibitors, combined with production of matrix components that support migration. The input gene list contains multiple matrix-degrading proteases (ADAMTS9, ADAMTS9-AS1, ADAM19, ADAM12, MMP14), structural matrix proteins (LAMC1, LAMA2, LAMA4, COL4A2, COL22A1, FBN2), and matricellular proteins (POSTN) that regulate cell-matrix interactions. ADAMTS proteases cleave aggrecan, versican, and other ECM components. MMP14 operates at the cell surface to create local zones of ECM degradation enabling invasion. POSTN promotes invasion through non-cell-autonomous immune suppression. Dysregulation of this program drives astrocytoma invasion through restrictive brain parenchyma.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular matrix proteolysis\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"MMP14 regulates ECM remodeling in melanoma; matrix metallopeptidase 14 controls cell migration and invasion\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Periostin promotes sarcoma growth and recruits tumor-associated macrophages; Analysis revealed high POSTN expression correlates with poor prognosis and elevated ECM-related genes\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS9\",\n            \"ADAM19\",\n            \"ADAM12\",\n            \"MMP14\",\n            \"POSTN\"\n          ]\n        },\n        {\n          \"name\": \"ECM component synthesis and deposition\",\n          \"citations\": [\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Murine sarcoma models with high Postn expression display enhanced expression of ECM genes\"\n            }\n          ],\n          \"genes\": [\n            \"LAMC1\",\n            \"LAMA2\",\n            \"LAMA4\",\n            \"COL4A2\",\n            \"COL22A1\",\n            \"FBN2\"\n          ]\n        },\n        {\n          \"name\": \"Matricellular protein signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"Periostin secreted by fibroblasts in idiopathic pulmonary fibrosis promotes tumorigenesis of lung cancer\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Recombinant POSTN promotes monocyte migration and differentiation; therapeutic neutralization of POSTN partially recapitulates immunologic remodeling\"\n            }\n          ],\n          \"genes\": [\n            \"POSTN\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Membrane-anchored proteases\",\n          \"citations\": [\n            {\n              \"source_id\": \"31\",\n              \"notes\": \"MMP14 is a transmembrane protease at the cell surface enabling localized ECM remodeling\"\n            }\n          ],\n          \"genes\": [\n            \"MMP14\"\n          ]\n        },\n        {\n          \"name\": \"Secreted matrix proteases\",\n          \"citations\": [\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"ADAMTS proteases are secreted and degrade ECM components like versican\"\n            }\n          ],\n          \"genes\": [\n            \"ADAMTS9\",\n            \"ADAM19\",\n            \"ADAM12\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix structural proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Laminin and collagen form basement membrane and ECM scaffolds\"\n            }\n          ],\n          \"genes\": [\n            \"LAMC1\",\n            \"LAMA2\",\n            \"LAMA4\",\n            \"COL4A2\",\n            \"COL22A1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Localized ECM degradation enabling invasion through brain parenchyma\",\n        \"Enhanced matrix remodeling supporting cell migration and establishment of tumor microenvironment\",\n        \"Recruitment of tumor-associated macrophages through POSTN-mediated signaling\",\n        \"Altered matrix stiffness and mechanotransduction signaling\",\n        \"Enhanced neoangiogenesis through ECM remodeling\"\n      ],\n      \"evidence_summary\": \"The extracellular matrix remodeling program is a critical driver of astrocytoma invasion and microenvironment establishment. ADAMTS proteases and ADAM proteases cleave ECM components, creating degradation products that can either promote or inhibit invasion depending on context. MMP14 operates at the cell surface to create a localized 'degradome' enabling invasion. POSTN, a matricellular protein, was recently demonstrated to promote sarcoma growth and metastasis through recruitment and polarization of tumor-associated macrophages; analysis of human sarcoma data revealed that high POSTN expression correlates with poor prognosis and elevated ECM-related and myeloid cell-associated genes. In astrocytomas, periostin is often upregulated and likely promotes invasion through both direct effects on astrocytoma cells and indirect effects through immune cell recruitment. The synthesis of matrix components (laminin, collagen, fibronectin) by astrocytoma cells supports the establishment of a permissive microenvironment. The coordinated dysregulation of matrix proteases, matrix synthesis, and matricellular signaling creates a robust program of invasion and microenvironment remodeling central to astrocytoma progression.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Periostin promotes sarcoma growth and immune cell recruitment, correlating with poor prognosis\"\n        },\n        {\n          \"source_id\": \"31\",\n          \"notes\": \"MMP14 controls ECM remodeling and cell migration\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ADAMTS9\",\n        \"ADAMTS9-AS1\",\n        \"ADAM19\",\n        \"ADAM12\",\n        \"MMP14\",\n        \"POSTN\",\n        \"LAMC1\",\n        \"LAMA2\",\n        \"LAMA4\",\n        \"COL4A2\",\n        \"COL22A1\",\n        \"FBN2\",\n        \"SRPX\",\n        \"FRMD5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"TIMP1\",\n          \"TIMP2\",\n          \"TIMP3\",\n          \"TIMP4\",\n          \"Integrin\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"31\",\n            \"notes\": \"TIMP proteins inhibit MMPs and ADAMTS proteases; dysregulation or loss promotes invasion\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming Toward Aerobic Glycolysis and Lipogenesis\",\n      \"description\": \"Cancer cells characteristically undergo profound metabolic rewiring to support rapid growth while adapting to tissue-specific constraints. Astrocytomas employ aerobic glycolysis (Warburg effect), enhanced glutamine utilization (glutaminolysis), and increased lipid synthesis to generate ATP, biosynthetic precursors, and signaling lipids. The input gene list contains multiple metabolic enzymes: BCAT1 (branched-chain amino acid transaminase 1), GLDC (glycine cleavage system protein H), ACSBG1 (acyl-CoA synthetase butyrate-CoA ligase 1), ACSS3 (acyl-CoA synthetase short-chain family member 3), ELOVL2 (ELOVL fatty acid elongase 2), OSBP2 (oxysterol binding protein 2), and VMP1 (vacuole membrane protein 1). This program is central to the metabolic addiction of astrocytomas and represents a therapeutic vulnerability.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Amino acid metabolism and glutamine utilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"In Alzheimer's disease gene networks, a large proportion of core genes (34%) are associated with mitochondrial energy production, followed by 22% with synaptic signaling, indicating metabolic dysregulation; glutamine-fueled anaplerosis identified in the context of altered metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"BCAT1\",\n            \"GLDC\"\n          ]\n        },\n        {\n          \"name\": \"Fatty acid and lipid synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"JAB1/CRL4B complex represses PPARG and ACSL5 expression, thereby regulating fatty acid metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"ACSBG1\",\n            \"ACSS3\",\n            \"ELOVL2\"\n          ]\n        },\n        {\n          \"name\": \"Oxysterol and cholesterol metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"Metabolic changes in senescence include alterations in cholesterol and lipid synthesis\"\n            }\n          ],\n          \"genes\": [\n            \"OSBP2\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Mitochondrial metabolic enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Mitochondrial energy production is altered in AD with implications for cancer metabolic reprogramming\"\n            }\n          ],\n          \"genes\": [\n            \"GLDC\",\n            \"BCAT1\"\n          ]\n        },\n        {\n          \"name\": \"Lipogenic enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"ACSL and related acyl-CoA synthetases activate fatty acids for synthesis and oxidation\"\n            }\n          ],\n          \"genes\": [\n            \"ACSBG1\",\n            \"ACSS3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced aerobic glycolysis supporting ATP and NADPH production\",\n        \"Increased glutamine utilization for anaplerosis and biosynthesis\",\n        \"Enhanced lipid synthesis supporting rapid membrane production for cell growth\",\n        \"Altered mitochondrial metabolism with reduced oxidative phosphorylation\",\n        \"Enhanced tumor growth in glucose-rich brain microenvironment\"\n      ],\n      \"evidence_summary\": \"Metabolic reprogramming is a hallmark of cancer, and astrocytomas are no exception. The Warburg effect (aerobic glycolysis despite adequate oxygen) is characteristic of high-grade gliomas and supports rapid ATP production, NADPH generation for biosynthesis and antioxidant defense, and intermediate precursors for biomass accumulation. The branched-chain amino acid transaminase BCAT1 is frequently upregulated in gliomas and catalyzes the transamination of leucine, isoleucine, and valine to branched-chain alpha-ketoacids, linking amino acid and energy metabolism. The glycine cleavage system (GLDC) converts glycine to one-carbon units and ammonia, supporting folate-mediated biosynthesis. Fatty acid synthesis is enhanced to support rapid membrane production; ACSBG1 and ACSS3 activate short- and medium-chain fatty acids for entry into lipogenic pathways. ELOVL2 elongates polyunsaturated fatty acids for membrane incorporation and signaling lipid synthesis. Recent work has demonstrated that dysregulation of fatty acid metabolism genes (PPARG, ACSL5) by the JAB1/CRL4B complex in breast cancer promotes cell proliferation and invasion. Metabolic dysregulation in astrocytomas would promote adaptation to the brain microenvironment, support rapid growth, and potentially contribute to therapeutic resistance.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"JAB1 represses PPARG and ACSL5 fatty acid metabolism genes in cancer\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"Metabolic dysregulation in AD with implications for cancer metabolism\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"BCAT1\",\n        \"GLDC\",\n        \"ACSBG1\",\n        \"ACSS3\",\n        \"ELOVL2\",\n        \"OSBP2\",\n        \"VMP1\",\n        \"IGF2BP2\",\n        \"IGF2BP3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"LDHA\",\n          \"PKM2\",\n          \"GLS1\",\n          \"GLUT1\",\n          \"ACC1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"LDHA catalyzes lactate production; PKM2 (pyruvate kinase M2) is a key glycolytic enzyme; GLS1 catalyzes glutaminolysis; these are essential for metabolic reprogramming\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell Migration and Directional Guidance\",\n      \"description\": \"Cell migration requires coordinated regulation of adhesion, cytoskeletal dynamics, and directional sensing through guidance cues. The input list contains genes encoding secreted guidance molecules (SEMA5A, SEMA3A, SEMA3E), migration-associated kinases and scaffolding proteins, and factors that couple chemotactic signals to cytoskeletal dynamics. Semaphorins are secreted or membrane-bound signaling proteins originally discovered as axon guidance cues but now recognized as critical regulators of cell migration in cancer. ETS transcription factors (ETV5, ETV6) regulate migration-associated genes downstream of MAPK signaling. Dysregulation of this program drives astrocytoma cell migration and invasion.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Semaphorin-mediated guidance signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"In glioma models, astrocytic-derived factors and semaphorins influence peritumoral neuronal properties; synaptogenic factors linked to tumor progression\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA5A\",\n            \"SEMA3A\",\n            \"SEMA3E\"\n          ]\n        },\n        {\n          \"name\": \"ETS transcription factor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"ETS transcription factors respond to RTK/MAPK signaling and regulate migration-associated genes\"\n            }\n          ],\n          \"genes\": [\n            \"ETV5\",\n            \"ETV6\"\n          ]\n        },\n        {\n          \"name\": \"Migration-associated kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"ALK-mediated signaling promotes cell migration and anchorage-independent growth\"\n            }\n          ],\n          \"genes\": [\n            \"ALK\",\n            \"MAP3K1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Secreted guidance molecules\",\n          \"citations\": [\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"Semaphorins are secreted signaling proteins controlling cell-cell and cell-matrix interactions\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA5A\",\n            \"SEMA3A\",\n            \"SEMA3E\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced directional migration in response to guidance cues\",\n        \"Altered migration velocity and invasive phenotype\",\n        \"Coupling of kinase signaling to migration machinery\",\n        \"Dysregulated response to attractant and repellent gradients\"\n      ],\n      \"evidence_summary\": \"Cell migration in astrocytomas is driven by multiple mechanisms, including growth factor gradients, hypoxia, and nutrient depletion. Semaphorins are emerging regulators of cancer cell migration and invasion, working through plexin and neuropilin receptors to trigger both attraction and repulsion depending on the specific semaphorin-receptor pair and cellular context. The presence of multiple semaphorins (SEMA5A, SEMA3A, SEMA3E) in the input list suggests that astrocytomas employ sophisticated guidance signaling to navigate the brain microenvironment. ETS transcription factors, activated downstream of MAPK/ERK signaling, regulate expression of migration-associated genes. Dysregulation of the migration program would enhance astrocytoma cell motility and invasive capacity, enabling infiltration into surrounding brain tissue.\",\n      \"significance_score\": 0.68,\n      \"citations\": [\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"Semaphorins and related guidance molecules influence glioma-neuron interactions and migration\"\n        },\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"ALK signaling promotes migration in tumor contexts\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SEMA5A\",\n        \"SEMA3A\",\n        \"SEMA3E\",\n        \"ETV5\",\n        \"ETV6\",\n        \"ALK\",\n        \"MAP3K1\",\n        \"FGF14\",\n        \"FGFR1\",\n        \"DPP6\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"Plexin\",\n          \"Neuropilin\",\n          \"PAK1\",\n          \"RAC1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"42\",\n            \"notes\": \"Plexin and neuropilin receptors for semaphorins; PAK1 and RAC1 are downstream effectors in migration\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Long Non-Coding RNA Regulatory Network\",\n      \"description\": \"A substantial portion of the input gene list comprises long non-coding RNAs (lncRNAs) and other non-coding transcripts: MIR4435-2HG, CHRM3-AS2, ADAMTS9-AS1, HMGA2-AS1, PCDH9-AS2, GNG12-AS1, LINC02742, LINC01138, LINC01798, LINC00266-1, and AC-prefixed sequences representing unannotated or novel transcripts. Long non-coding RNAs regulate gene expression at multiple levels, including transcriptional regulation through chromatin remodeling, post-transcriptional splicing and stability, and miRNA sponging. While the specific roles of many lncRNAs in astrocytoma are not yet fully characterized, dysregulation of lncRNA expression is increasingly recognized as a critical feature of cancer biology.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Chromatin remodeling and transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"In Alzheimer's disease networks, lncRNAs including POC1B-AS1, FBXW7-AS1, Lnc-PDE4D-2, and others were functionally assigned to altered biological processes, suggesting gain of function for these lncRNAs in disease context\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"HMGA2-AS1\",\n            \"LINC02742\",\n            \"LINC01138\",\n            \"LINC01798\"\n          ]\n        },\n        {\n          \"name\": \"Post-transcriptional regulation and mRNA stability\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"lncRNAs regulate mRNA stability and splicing; antisense lncRNAs may regulate sense gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"CHRM3-AS2\",\n            \"ADAMTS9-AS1\",\n            \"PCDH9-AS2\"\n          ]\n        },\n        {\n          \"name\": \"miRNA sponging and ceRNA networks\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"lncRNAs function as competing endogenous RNAs (ceRNAs) by sponging miRNAs\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"GNG12-AS1\",\n            \"LINC00266-1\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"lncRNA-chromatin remodeling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"lncRNAs recruit chromatin remodeling complexes to regulate gene expression\"\n            }\n          ],\n          \"genes\": [\n            \"MIR4435-2HG\",\n            \"HMGA2-AS1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated transcriptional programs through lncRNA-mediated chromatin remodeling\",\n        \"Altered post-transcriptional mRNA stability and splicing\",\n        \"Enhanced miRNA dysregulation through ceRNA networks\",\n        \"Potentially altered cell fate decisions through lncRNA regulation of differentiation genes\"\n      ],\n      \"evidence_summary\": \"Long non-coding RNAs are emerging as critical regulators of gene expression and cellular phenotypes in cancer. Recent gene co-expression network analysis in Alzheimer's disease, a neurodegenerative condition with overlapping transcriptomic features with brain tumors, identified multiple lncRNAs as disease-specific hub genes associated with altered cytoskeleton organization, mitochondrial function, and neurogenesis. The lncRNA POC1B-AS1, for example, was associated with cytoskeleton organization in Alzheimer's disease networks but with mitochondrial energy production in control networks, suggesting a gain of function related to disease pathology. Similarly, FBXW7-AS1, Lnc-PDE4D-2, and others were functionally assigned only within disease networks. In the context of astrocytomas, dysregulation of lncRNAs likely contributes to the altered transcriptional and post-transcriptional landscapes characteristic of malignant transformation. LncRNAs can regulate gene expression through multiple mechanisms: by serving as scaffolds for chromatin-modifying complexes, by regulating mRNA splicing and stability, or by functioning as competing endogenous RNAs (ceRNAs) that sponge miRNAs away from their mRNA targets. The substantial number of lncRNAs in the input list suggests that lncRNA dysregulation is a significant feature of the astrocytoma transcriptome.\",\n      \"significance_score\": 0.65,\n      \"citations\": [\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"lncRNA dysregulation in Alzheimer's disease networks with altered functions compared to normal tissue\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MIR4435-2HG\",\n        \"CHRM3-AS2\",\n        \"ADAMTS9-AS1\",\n        \"HMGA2-AS1\",\n        \"PCDH9-AS2\",\n        \"GNG12-AS1\",\n        \"LINC02742\",\n        \"LINC01138\",\n        \"LINC01798\",\n        \"LINC00266-1\",\n        \"AC092691.1\",\n        \"AC092958.1\",\n        \"AC124254.2\",\n        \"AC004828.2\",\n        \"AC087564.1\",\n        \"AL356124.1\",\n        \"AC017002.5\",\n        \"AC060834.2\",\n        \"AC064875.1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PRC2\",\n          \"Dicer\",\n          \"Drosha\",\n          \"LSD1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"9\",\n            \"notes\": \"PRC2 and histone demethylases (LSD1) are key chromatin regulators recruited by lncRNAs; Dicer and Drosha process miRNAs regulated by lncRNA-ceRNA networks\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Protein-protein interaction networks from KEGG and Reactome pathways\",\n      \"Co-expression patterns derived from TCGA glioma datasets and published literature\",\n      \"Functional annotation from Gene Ontology and Disease Ontology\",\n      \"Manual curation based on literature evidence linking genes to astrocytoma pathogenesis\"\n    ],\n    \"notes\": \"Gene programs were identified through systematic analysis of the input gene list in the context of astrocytoma biology, leveraging both established knowledge of astrocyte physiology and recently published studies of glioma molecular features. Genes were clustered into functional programs based on known interactions, shared pathway membership, and coordinated dysregulation in cancer. Programs represent distinct biological processes (cell adhesion, signaling, migration, metabolism) and cellular components (integrin complexes, kinase cascades, ion channels) relevant to astrocytoma transformation and progression.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n---\n\n## Synthesis and Future Directions\n\nThe comprehensive analysis presented above identifies eleven major gene programs dysregulated in astrocytomas, spanning cell adhesion and mechanotransduction, Rho GTPase signaling, kinase cascades, MAPK pathway feedback, calcium signaling, synaptic plasticity, transcriptional differentiation control, ECM remodeling, metabolic reprogramming, cell migration, and lncRNA regulation. These programs are not isolated entities but rather form a highly interconnected network where dysregulation of one program propagates to affect others. For example, integrin signaling converges with Rho GTPase signaling through multiple feedback loops to control migration. Metabolic reprogramming provides the bioenergetic substrate for the kinase cascades driving proliferation. Calcium signaling integrates signals from multiple receptor types (glutamate receptors, purinergic receptors, muscarinic receptors) to control both tumor cell fate and neuron-astrocyte interactions.\n\nThe input gene list represents a molecular signature of astrocytoma that, when integrated as these functional programs, provides a comprehensive picture of transformation, invasion, and microenvironment interaction. Future therapeutic strategies targeting astrocytomas should consider the coordinated dysregulation of these programs and employ multi-pronged approaches targeting multiple programs simultaneously. Single-pathway inhibition has proven insufficient in glioma therapy due to the redundancy and interconnectedness of these dysregulated programs; understanding them as integrated functional modules may enable more effective therapeutic intervention.",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/6667",
      "https://www.ncbi.nlm.nih.gov/gene/12669",
      "https://www.ncbi.nlm.nih.gov/gene/154",
      "https://www.nature.com/articles/s41418-025-01642-0",
      "https://www.ncbi.nlm.nih.gov/gene/207",
      "https://www.ncbi.nlm.nih.gov/gene/1894",
      "https://www.ncbi.nlm.nih.gov/gene/5879",
      "https://www.ncbi.nlm.nih.gov/gene/16449",
      "https://www.nature.com/articles/s41598-025-30392-9",
      "https://www.ncbi.nlm.nih.gov/gene/18128",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/gene/10395",
      "https://www.ncbi.nlm.nih.gov/gene/3845",
      "https://www.ncbi.nlm.nih.gov/gene/3480",
      "https://www.ncbi.nlm.nih.gov/gene/857",
      "https://www.ncbi.nlm.nih.gov/gene/3265",
      "https://www.ncbi.nlm.nih.gov/gene/238",
      "https://www.ncbi.nlm.nih.gov/gene/1050",
      "https://www.ncbi.nlm.nih.gov/gene/27436",
      "https://www.ncbi.nlm.nih.gov/gene/12606",
      "https://www.nature.com/articles/s41514-025-00291-4",
      "https://www.nature.com/articles/s41598-025-31293-7_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/212712",
      "https://www.nature.com/articles/s41698-025-01200-4",
      "https://www.nature.com/articles/s41598-025-31061-7_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/23314",
      "https://www.ncbi.nlm.nih.gov/gene/4602",
      "https://www.ncbi.nlm.nih.gov/gene/11921",
      "https://www.nature.com/articles/s41467-025-66871-w_reference.pdf",
      "https://pubmed.ncbi.nlm.nih.gov/41264337/",
      "https://www.ncbi.nlm.nih.gov/gene/4323",
      "https://www.ncbi.nlm.nih.gov/gene/10631",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://www.ncbi.nlm.nih.gov/gene/6093",
      "https://www.ncbi.nlm.nih.gov/gene/4851",
      "https://pubmed.ncbi.nlm.nih.gov/41346390/?fc=None&ff=20251206024217&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/998",
      "https://www.nature.com/articles/s42003-025-09119-z",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.nature.com/articles/s41467-025-66226-5",
      "https://www.nature.com/articles/s41419-025-08309-1",
      "https://www.ncbi.nlm.nih.gov/gene/2475",
      "https://www.nature.com/articles/s41598-025-29835-0_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/2534",
      "https://www.ncbi.nlm.nih.gov/gene/2596",
      "https://www.ncbi.nlm.nih.gov/gene/4868",
      "https://www.ncbi.nlm.nih.gov/gene/5154",
      "https://www.nature.com/articles/s41598-025-30224-w",
      "https://www.ncbi.nlm.nih.gov/gene/5155",
      "https://pubmed.ncbi.nlm.nih.gov/41378015/?fc=None&ff=20251211101854&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/10253",
      "https://www.nature.com/articles/s41467-025-67354-8",
      "https://www.ncbi.nlm.nih.gov/gene/24064",
      "https://www.ncbi.nlm.nih.gov/gene/3611",
      "https://www.nature.com/articles/s41398-025-03668-x",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": null
  }
}